Haven't been much on this board lately because of all the BS from shorts. So if this has already been discussed, I missed it. ? is about the cervical dysplasia program. It seems Merck has similar product further along than we do. Is this so? Are they using electroporation for this program. If so & they are approved before us to market it, our agreement should provide significant revenue for E delivery method. Would the license cover the latest that Cellectra has to offer for us or would it be only for the older technology? If this is so, they would have to re-negotiate agreement & offer more $'s for the latest, more effective means. Appreciate any answers to my ?'s. Or if I am wrong on anything, Please advise.
Take politics SOME WHERE ELSE! You have screwed up a good board with this nonsense. You are not going to change any of our views. You may be L, R, or C politically. And that's ok. I, for one, prefer discussion here be about ATRS. I don't normally post. Just enjoyed reading here before you started this.